Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles

Albuquerque, L.E.T.; Saconato, Humberto; Maciel, Maria Cecília Romano; Tso, L.O.

doi:10.1002/14651858.cd002808.pub2

Cited by 11 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depot GnRHa in long protocols offers the advantages of better compliance, convenience, and economy for patients, with less stress over injections and risk of infection. However, depot formulations require more gonadotropin ampoules, which are needed for ovarian stimulation, and a significantly longer duration of ovarian stimulation than daily GnRHa [7]. …”

Section: Discussionmentioning

confidence: 99%

“…in a meta-analysis study [7] showed that there is insufficient evidence that the depot GnRH agonist formulation is better or worse than using a daily GnRH agonist in the long protocol for pituitary desensitization in IVF cycles; so clinicians should use whichever is more convenient [7]. According to their recommendations, the present study was done on infertile women with both ovaries undergoing their first IVF cycles.…”

Section: Discussionmentioning

confidence: 99%

“…It is welcomed, both by patients and physicians, because of the convenience of a single administration [6]. However, when profound pituitary desensitization is induced, there is an increase in the number of used gonadotropin ampoules and the duration of the COS cycle without improving pregnancy rates or other clinical outcomes [7]. Although some researchers such as Genon et al .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles

Tehraninejad¹,

Nekoo²,

Ezabadi³

et al. 2010

aoms

View full text Add to dashboard Cite

IntroductionThe aim of the study was to compare the efficacy of half-dose, long-acting GnRH analogue (Diphereline) with Suprefact in IVF/ICSI (in vitro fertilization/intracytoplasmic sperm injection) cycles.Material and methodsIn this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled. Patients were randomly divided into two groups by using a random number table. In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase. In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase. P value less than 0.05 was considered significant.ResultsThe mean age of patients in the Diphereline and Suprefact groups was 27.9 ±3.6 and 29.6 ±3.5 years, respectively (p = 0.01). In the Diphereline group, the mean number of used gonadotropins was 25.6 ±12.1 ampoules, while in the second group it was 25.9 ±8.5 ampoules. Numbers of retrieved and MII oocytes were significantly higher in the Diphereline group (12.1 ±6.3 and 9.6 ±5.5) in comparison to the Suprefact group (9.4 ±6.4 and 7.2 ±5.1). Although the number of developed embryos in the Diphereline group was statistically higher than in the Suprefact group (6.1 ±3.9 vs. 4.7 ±3.4, p = 0.04) there was no significant difference in pregnancy rate (37.1%, 95% CI [26.16-49.54] vs. 37.5%, 95% CI [26.67-49.75]).ConclusionsA half-dose, long-acting GnRH agonist can be successfully used in ovarian stimulation and produces a higher number of MII oocytes and embryos. The pregnancy rates with this method are acceptable.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles

Tehraninejad¹,

Nekoo²,

Ezabadi³

et al. 2010

aoms

View full text Add to dashboard Cite

show abstract

“…Differences in various GnRHa concerning intensity, onset and duration of pituitary suppression have been demonstrated previously (11)(12)(13). A recent meta-analysis did not demonstrate significant differences between patients treated with depot or daily GnRH agonists in terms of pregnancy rate, but number of gonadotrophin ampoules and duration of stimulation (14). However, none of the studies included used recombinant FSH devoid of any additional LH activity for ovarian stimulation.…”

Section: Introductionmentioning

confidence: 87%

Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART

Sonntag¹,

Kiesel²,

Nieschlag³

et al. 2005

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…However, because of oversuppression, the ampoules of gonadotrophin used and the duration of COS cycle were increased without improving clinical outcomes when depot GnRHa was compared with daily-low-dose GnRHa in a recent Cochrane Review. [3]…”

Section: Introductionmentioning

confidence: 99%

Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation

Yu¹,

Yang²,

Zhang³

2012

J Hum Reprod Sci

View full text Add to dashboard Cite

OBJECTIVE:Appropriate dosage of the long-acting depot gonadotrophin releasing hormone (GnRH) agonist has not been determined in long protocol for IVF, and one-third-dose depot triptorelin was compared with half-dose in a luteal long protocol of in-vitro fertilization/ intra cytoplasmic sperm injection (IVF/ICSI) treatment in this study.MATERIALS AND METHODS:This is a prospective, randomized, open clinical trial. 100 patients were randomized into two groups. Group I received one-third-dose (1.25 mg) depot triptorelin. Group II received half-dose (1.87 mg). The clinical and experimental parameters were compared between the two groups.RESULTS:There was no premature luteinizing hormone (LH) surge in both groups. On Day 3–5 of menstrual cycle after down-regulation, fewer patients showed low-level LH (<1.0 IU/L) and estradiol (<30 pg/mL) in group I (P <0.05). There were fewer oocytes retrieved (P =0.086), fewer total embryos and available embryos for cryopreservation in Group I (P <0.05), while good-quality embryo rate was higher in group I (P <0.05). The length and dose of ovarian stimulation was lower in Group I, but not significantly. The clinical pregnancy (52% versus 40%), implantation (48% versus 37.5%), delivery (46% versus 32%), or live birth (42% versus 32%) rates and the abortion (8% versus 20%) rates showed no significant differences.CONCLUSION:Depot triptorelin 1.25 mg can be successfully used with reduced pituitary suppression and lower cost in a long protocol for in-vitro fertilization.

show abstract

Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles

Cited by 11 publications

References 39 publications

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles

Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART

Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation

Contact Info

Product

Resources

About